Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
FDA-approved: Relief of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.,Off-label: Treatment of apnea of prematurity (limited use).
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in neonates, elderly, and patients with hepatic or cardiac dysfunction. Theophylline is a narrow therapeutic index drug; half-life dictates dosing frequency and need for therapeutic drug monitoring.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Dyphylline is primarily metabolized by the liver via oxidation, with a smaller portion undergoing N-demethylation and oxidation. It is not metabolized to theophylline. Approximately 80% of the dose is excreted unchanged in the urine, indicating minimal hepatic metabolism.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal: approximately 50% unchanged drug; biliary/fecal: minimal (less than 10%). The remainder undergoes hepatic metabolism.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3-0.7 L/kg, approximating total body water; higher in neonates and patients with decreased protein binding (e.g., hepatic disease).
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 100% (well absorbed); Extended-release formulations have comparable bioavailability with slower absorption.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
Cr Cl 50-80 m L/min: 75% of dose; Cr Cl 25-50 m L/min: 50% of dose; Cr Cl <25 m L/min: 25% of dose; hemodialysis: administer after dialysis at 50% of dose.
No adjustment required as drug is primarily hepatically metabolized.
No specific Child-Pugh based adjustments established; use with caution in severe hepatic impairment due to potential reduced clearance.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Not recommended for use in children; safety and efficacy not established. If used: 3-5 mg/kg orally every 6 hours, titrate to serum levels.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lower end of dosing (200 mg every 6 hours) due to potential age-related decline in renal function; monitor serum levels and adjust based on Cr Cl.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
None
None.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, glaucoma, diabetes mellitus, severe hypoxemia, hypertension, arrhythmias, congestive heart failure, and renal impairment. Monitor serum levels; toxicity can occur at high doses. Concurrent use with other xanthines may increase toxicity. May cause seizures, arrhythmias, and death if serum levels exceed the therapeutic range.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to dyphylline or any component of the formulation; history of seizure disorder (unless adequately controlled); active gastrointestinal hemorrhage; concurrent use of other xanthine derivatives (e.g., theophylline, caffeine).
Hypersensitivity to theophylline or any component of the formulation.
Avoid large amounts of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase the risk of side effects like nervousness and palpitations. No other significant food interactions.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. Fetal risks are considered low, but caution is advised during all trimesters.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Diprophylline is excreted into human milk. The M/P ratio is unknown. Potential adverse effects in infants include irritability and poor feeding. Weigh benefits against risks. Consider alternative bronchodilators if possible.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
No specific dose adjustments recommended due to pregnancy. Pharmacokinetic changes in pregnancy may decrease drug clearance; monitor clinical response and adjust dose if needed based on efficacy and toxicity.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
DILOR (diprophylline) is a xanthine bronchodilator less potent than theophylline but with fewer GI side effects; monitor for nausea, tremor, tachycardia; use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders; drug interactions include cimetidine, fluoroquinolones, and oral contraceptives which decrease clearance; theophylline levels are not routinely measured but toxicity can occur at high doses.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not double doses.,Report persistent nausea, vomiting, rapid heartbeat, or chest pain.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Inform all healthcare providers you are taking this medication.,Do not stop abruptly without consulting your doctor.,Store at room temperature away from heat and moisture.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR vs AEROLATE JR, answered by our medical review team.
DILOR is a Bronchodilator that works by DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR is: DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR is classified as Category C. DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot . AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.